Harrison, Hannah
Ip, Samantha
Renzi, Cristina
Li, Yangfan
Barclay, Matthew
Usher-Smith, Juliet
Lyratzopoulos, Georgios
Wood, Angela
Antoniou, Antonis C.
Funding for this research was provided by:
International Alliance for Cancer Early Detection (ACEDFR3_0620I135PR007, ACEDFR3_0620I135PR007, ACEDFR3_0620I135PR007)
CRUK International Alliance for Cancer Early Detection (EDDAPA-2022/100001, EDDAPA-2022/100002)
Cancer Research UK (EDDPMA-May22\100062, C18081/A18180, PPRPGM-Nov20\100002)
Cancer Research UK - Early Detection and Diagnosis Committee (EDDCPJT\100018)
National Institute of Health Research Advanced Fellowship (NIHR300861)
British Heart Foundation (RG/13/13/30194; RG/18/13/33946)
NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
BHF-Turing Cardiovascular Data Science Award (BCDSA\100005)
BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking (116074)
Article History
Received: 18 July 2023
Accepted: 6 February 2024
First Online: 20 March 2024
Declarations
:
: The UK Biobank study was approved by the North West Multi- Centre Research Ethics Committee (reference number 06/MRE09/ 65), and at recruitment all participants gave informed written consent to participate in UK Biobank and be followed up in accordance with the Declaration of Helsinki.Data storage and access for this project was strictly controlled in accordance with the data agreements between the researchers and UK Biobank. Access to this data was approved by UK Biobank under project 64351 (Risk-stratified early detection and diagnosis of cancer using linked electronic health records (RREDD-HER)) and 28126 (Validating risk prediction models for common hormonal cancers). Throughout the project the data was stored and accessed only via a secure sever at the Centre for Cancer Genetic Epidemiology (DPHPC, University of Cambridge).
: Not applicable.
: The authors declare no competing interests.